Background illustration for clinical trials search

Pancreatic Cancer Clinical Trials

Browse 1,722 pancreatic cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1
Active & Responsive

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

for
Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer,
Location: New Haven CT, Lake Success NY, New York NY, Fairfax VA,
Sponsor: Cogent Biosciences, Inc.

Sex: All

Age: 18+

Code: NCT07361562

Phase 1, Recruiting
Active & Responsive

Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

for
Glioblastoma Multiforme (GBM), Glioblastoma, Glioma of Brain,
Location: New York NY
Sponsor: Northwell Health

Sex: All

Age: 18 - 70+

Code: NCT03213002

Phase 1, Phase 2, Recruiting
Active & Responsive

UWCCC Molecular Tumor Board Registry

for
Hematologic Neoplasms, Solid Neoplasm
Location: Madison WI
Sponsor: University of Wisconsin, Madison

Sex: All

Age: 18+

Code: NCT03023202

Recruiting
Active & Responsive

Biennial CEM in Women With a Personal History of Breast Cancer

for
Breast Cancer, Breast Neoplasms, Breast Cancer Female,
Location: Monroeville PA, West Mifflin PA, Pittsburgh PA,
Sponsor: Wendie Berg

Sex: Female

Age: 30 - 70+

Code: NCT06105749

Recruiting
Active & Responsive

68Ga-PSMA-617 PET/CT for PSMA-expressing Tumor: a Pragmatic Study

for
Solid Cancers
Location: Sherbrooke
Sponsor: Centre de recherche du Centre hospitalier universitaire de Sherbrooke

Sex: All

Age: 0+

Code: NCT05228106

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors

for
Solid Tumor
Location: Canton OH, Cleveland OH
Sponsor: Lamassu Bio Inc

Sex: All

Age: 18+

Code: NCT06578624

Phase 1, Phase 2, Recruiting
Active & Responsive

Yoga for Young Adults Affected by Cancer

for
Young Adult Cancer, Young Adult Oncology
Location: Calgary
Sponsor: University of Calgary

Sex: All

Age: 18+

Code: NCT05314803

Recruiting
Active & Responsive

PAS-004 in Patients With Advanced Solid Tumors

for
RAS Mutation, NF1 Mutation, RAF Mutation, Advanced Solid Tumors
Location: Fairfax VA, San Antonio TX
Sponsor: Pasithea Therapeutics Corp.

Sex: All

Age: 18+

Code: NCT06299839

Phase 1, Recruiting
Active & Responsive

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

for
Solid Tumors
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06066424

Phase 1, Recruiting
Active & Responsive

Multisite Implementation of COMPRENDO

for
Pediatric Cancer
Location: Boston MA, Birmingham AL, San Diego CA,
Sponsor: University of California, San Diego

Sex: All

Age: 18+

Code: NCT06055296

Recruiting
Active & Responsive

Biomarkers to Detect Endocrine Therapy Resistance

for
Metastatic Cancer, Breast Cancer, Lobular Breast Carcinoma
Location: Madison WI
Sponsor: University of Wisconsin, Madison

Sex: All

Age: 18+

Code: NCT06067503

Phase 2, Recruiting
Active & Responsive

CARE Study: Cancer, Asian Americans, and Relationship Enrichment

for
Neoplasm
Location: Philadelphia PA
Sponsor: Fox Chase Cancer Center

Sex: All

Age: 21 - 70+

Code: NCT06782581

Recruiting
Active & Responsive

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

for
Solid Tumor, KRAS Mutation-Related Tumors
Location: Washington D.C. DC
Sponsor: Georgetown University

Sex: All

Age: 18+

Code: NCT05661201

Phase 1, Recruiting
Active & Responsive

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

for
Localized Renal Pelvis and Ureter Urothelial Carcinoma,
Location: Seattle WA
Sponsor: University of Washington

Sex: Male

Age: 18+

Code: NCT01050504

Recruiting
Active & Responsive

MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other

for
Cancer, Adjustment Disorders
Location: Rockville MD
Sponsor: Sunstone Medical

Sex: All

Age: 18+

Code: NCT05584826

Phase 2, Recruiting
Active & Responsive

PATH Program for for Severely Frail or Cognitively Impaired Patients Scheduled for Cancer Surgery.

for
Frailty, Oncology Problem, Cognitive Impairment
Location: Halifax
Sponsor: Nova Scotia Health Authority

Sex: All

Age: 70+

Code: NCT06022666

Recruiting
Active & Responsive

A Study of PHST001 in Advanced Solid Tumors

for
Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer,
Location: Boston MA, New Haven CT, Lake Success NY, New York NY,
Sponsor: Pheast Therapeutics

Sex: All

Age: 18+

Code: NCT06840886

Phase 1, Recruiting
Active & Responsive

Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors

for
Solid Tumor
Location: Pittsburgh PA, Atlanta GA, St Louis MO, Houston TX
Sponsor: Emory University

Sex: All

Age: 1 - 30

Code: NCT04469530

Phase 2, Recruiting
Active & Responsive

Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions

for
Pheochromocytoma, Paraganglioma, Inherited Cancer Syndrome,
Location: San Antonio TX
Sponsor: The University of Texas Health Science Center at San Antonio

Sex: All

Age: 0+

Code: NCT03160274

Recruiting
Active & Responsive

A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors

for
Advanced Solid Tumors
Location: Fairfax VA, Houston TX, Fort Worth TX, San Antonio TX,
Sponsor: Antares Therapeutics, Inc

Sex: All

Age: 18+

Code: NCT07767474

Phase 1, Phase 2, Recruiting

What is pancreatic cancer?

The pancreas sits deep behind the stomach and makes both digestive enzymes and hormones like insulin. About 92 percent of pancreatic cancers start in the enzyme making cells, and this page is mostly about those. The other 8 percent are neuroendocrine tumors, which grow more slowly, have their own trials, and a five year survival of 72 percent against 8 percent. The pancreas gives no early warning. Jaundice, back pain, weight loss and new diabetes usually appear only after the cancer has grown or spread, and fewer than 20 percent of people can have surgery at diagnosis.

Smoking roughly doubles the risk, and type 2 diabetes, extra weight, chronic pancreatitis and family history raise it. About 10 percent of cases come from inherited mutations, so guidelines now recommend genetic testing for everyone diagnosed. That can change treatment and flag relatives who should be watched. The hope comes from biology. More than 90 percent of pancreatic cancers carry a KRAS mutation. That target was called undruggable for decades. Now several RAS inhibitors are in trials, with the first Phase 3 studies recruiting. Pancreatic cancer shares risk factors with type 2 diabetes and inherited genes with breast and ovarian cancer.

Article preview image

Our guide to new treatments for pancreatic cancer covers what has been approved and what is being tested.

Research Paving The Way To A New Treatment For Pancreatic Cancer

Types of pancreatic cancer clinical trials

Who can participate in pancreatic cancer clinical trials?

What causes pancreatic cancer?

The stages of pancreatic cancer, and why they matter for trials

How to enroll in a pancreatic cancer clinical trial